Vasculitis & polymyalgia rheumatica
Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort
Authors' conclusion
Data from the GCA and PMR cohorts imply a metabolic dysregulation in treatment-naïve patients with GCA, but not in patients with PMR. Treatment with GCs led to the rise of comorbidities and an unhealthier metabolic profile
Study context
- Population
- Treatment-naïve patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR), Dutch GCA/PMR/SENEX (GPS) cohort and Danish Aarhus cohort
- Participants
- 50 / 42 / 91 / 52 / 25
- Exposure
- Treatment-naïve GCA and PMR vs population-based Lifelines cohort
- GCA (GPS)n = 50
- PMR (GPS)n = 42
- Lifelinesn = 91reference
- GCA (Aarhus)n = 52
- PMR (Aarhus)n = 25
- Outcome
- Metabolic features and prevalence of comorbidities (type 2 diabetes, hypercholesterolaemia, hypertension, obesity and cataract)
Methodological detailscomparison with population-based Lifelines cohort, validation in Aarhus cohort, follow-up up to 5 years
- Comparison with population-based Lifelines cohort
- Validation in Aarhus cohort
- Follow-up up to 5 years
Main finding
As reported in the abstract
Metabolic features at baseline vs Lifelines · before treatment
- Glycated haemoglobin tended to be higher in treatment-naïve GCA vs Lifelines
- HDL, LDL and cholesterol levels lower in treatment-naïve GCA vs Lifelines
- Aarhus cohort data aligned with GPS cohort findings
Observational data: associations, not effects.
Further findings
- Presence of comorbidities at baseline did not predict long-term GC requirement
Original publication
Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort. RMD Open. Published 11 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →